Aggarwal Kanishk, Pathan Mayur Srinivas, Dhalani Mayank, Kaur Inder P, Anamika Fnu, Gupta Vasu, Jayaraman Dilip Kumar, Jain Rohit
Internal Medicine, Dayanand Medical College, Punjab, India.
Avalon University School of Medicine, Willemstad, Curacao.
Curr Cardiol Rev. 2025;21(2):19-26. doi: 10.2174/011573403X308818241030051249.
High-altitude regions pose distinctive challenges for cardiovascular health because of decreased oxygen levels, reduced barometric pressure, and colder temperatures. Approximately 82 million people live above 2400 meters, while over 100 million people visit these heights annually. Individuals ascending rapidly or those with pre-existing cardiovascular conditions are particularly vulnerable to altitude-related illnesses, including Acute Mountain Sickness (AMS) and Chronic Mountain Sickness (CMS). The cardiovascular system struggles to adapt to hypoxic stress, which can lead to arrhythmias, systemic hypertension, and right ventricular failure. Pathophysiologically, high-altitude exposure triggers immediate increases in cardiac output and heart rate, often due to enhanced sympathetic activity. Over time, acclimatisation involves complex changes, such as reduced stroke volume and increased blood volume. The pulmonary vasculature also undergoes significant alterations, including hypoxic pulmonary vasoconstriction and vascular remodelling, contributing to conditions, like pulmonary hypertension and high-altitude pulmonary edema. Genetic adaptations in populations living at high altitudes, such as gene variations linked to hypoxia response, further influence these physiological processes. Regarding cardiovascular disease risk, stable coronary artery disease patients generally do not face significant adverse outcomes at altitudes up to 3500 meters. However, those with unstable angina or recent cardiac interventions should avoid high-altitude exposure to prevent exacerbation. Remarkably, high-altitude living correlates with reduced cardiovascular mortality rates, possibly due to improved air quality and hypoxia-induced adaptations. Additionally, there is a higher incidence of congenital heart disease among children born at high altitudes, highlighting the profound impact of hypoxia on heart development. Understanding these dynamics is crucial for managing risks and improving health outcomes in high-altitude environments.
由于氧气水平降低、气压下降和气温较低,高海拔地区对心血管健康构成了独特的挑战。约有8200万人生活在海拔2400米以上的地区,而每年有超过1亿人前往这些高海拔地区。迅速上升的个体或已有心血管疾病的人特别容易患上与海拔相关的疾病,包括急性高山病(AMS)和慢性高山病(CMS)。心血管系统难以适应低氧应激,这可能导致心律失常、全身性高血压和右心室衰竭。从病理生理学角度来看,高海拔暴露通常会由于交感神经活动增强而立即导致心输出量和心率增加。随着时间的推移,适应过程涉及复杂的变化,如每搏输出量减少和血容量增加。肺血管系统也会发生显著改变,包括低氧性肺血管收缩和血管重塑,从而导致诸如肺动脉高压和高海拔肺水肿等病症。生活在高海拔地区的人群的基因适应性,如与低氧反应相关的基因变异,进一步影响这些生理过程。关于心血管疾病风险,稳定型冠状动脉疾病患者在海拔3500米以下一般不会面临重大不良后果。然而,那些患有不稳定型心绞痛或近期接受过心脏干预的患者应避免高海拔暴露,以防止病情加重。值得注意的是,高海拔地区的生活与心血管死亡率降低相关,这可能是由于空气质量改善和低氧诱导的适应性变化。此外,高海拔地区出生的儿童先天性心脏病的发病率较高,这突出了低氧对心脏发育的深远影响。了解这些动态对于管理高海拔环境中的风险和改善健康结果至关重要。